Glioblastoma Multiforme Key Companies
Oct 10, 2024
Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On
The present Glioblastoma multiforme (GBM) market has several unmet needs. Poor prognosis, 10-15 months median survival rate, no curative treatment to the patients, limited treatment options, drug resistance, incapability of therapies to cross BBB (blood-brain-barrier), intratumor heterogeneity, and a high mortality...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
